<DOC>
	<DOCNO>NCT01514149</DOCNO>
	<brief_summary>DM200-103 dose-ranging study evaluate efficacy safety 17 week weekly injection CJC-1134-PC patient Type 2 Diabetes Mellitus metformin monotherapy .</brief_summary>
	<brief_title>Dose-Ranging Study Evaluate Efficacy Safety Weekly CJC-1134-PC Patients With T2DM Metformin Monotherapy</brief_title>
	<detailed_description>DM200-103 dose-ranging study evaluate efficacy safety 17 week weekly injection CJC-1134-PC patient Type 2 Diabetes Mellitus ( T2DM ) metformin monotherapy . This study randomize , double-blind comparison CJC-1134-PC versus placebo . Patients take metformin continue take metformin dose duration study . Patients T2DM , meet inclusion criterion none exclusion criterion , randomly assign treatment arm . All patient undergo weekly clinic visit receive 17 week study treatment , include titration period . CJC-1134-PC placebo treatment administer weekly subcutaneous injection abdomen patient fast state . Patients closely monitor evaluated toxicity ongoing basis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Men woman 18 70 year age , inclusive Body mass index 27 45 kg/m2 Diagnosed T2DM least 6 month screen Stable daily dose metformin monotherapy ≥1000 mg least 3 month screen FPG ≤240 mg/dL screen HbA1c ≥7.0 % ≤11 % screen A 12lead electrocardiogram record without clinically significant arrhythmia , leave bundlebranch block , correct QT interval Pregnant breastfeed woman Use weight control treatment , include overthecounter medication ( include herbal supplement ) , significant change body weight ( least ±10 % ) 3 month screen Treatment oral antidiabetic agent metformin within 3 month screen Treatment insulin longer 1 week within 3 month screen treatment insulin within 2 week screen Previous treatment glucagonlike peptide 1 ( GLP1 ) analog incretin therapy Receipt experimental drug clinical trial within 30 day administration study drug receipt investigational antidiabetic product within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>T2DM</keyword>
	<keyword>diabetes</keyword>
	<keyword>ConjuChem</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Glucagon-like peptide-1</keyword>
	<keyword>exendin-4</keyword>
	<keyword>modify exendin-4</keyword>
</DOC>